Attal M, Richardson PG, Rajkumar SV, et al. - In this randomized, multicentre, open-label, phase 3 study done at 102 hospitals in 24 countries in Europe, North America, and the Asia-Pacific regions of adults with relapsed and refractory multiple myeloma who had received minimum two former lines of treatment, including lenalidomide and a proteasome inhibitor (n = 307), experts ascertained the progression-free survival advantage of isatuximab plus pomalidomide and dexamethasone in comparison with pomalidomide and dexamethasone in people with relapsed and refractory multiple myeloma. It was discovered that in people with relapsed and refractory multiple myeloma, progression-free survival was notably enhanced by adding isatuximab to pomalidomide–dexamethasone. Thus, for the management of relapsed and refractory myeloma, isatuximab is a significant new treatment choice, especially for people who become refractory to lenalidomide and a proteasome inhibitor.